Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study

Dore, Robin K.; Ballard, Ian M; Constantine, Ginger D.; McDonald, Patricia E.

doi:10.1016/0149-2918(95)80042-5

Cited by 21 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four trials did not present mean change data but only before and after means and P values 30 32 44 45. Eleven trials presented data on overall pain on 100 mm visual analogue scales or on a categorical five point scale,30 – 32 37 38 41 42 47 50 – 52 while the 12 remaining trials presented either categorical or continuous data from the WOMAC subscale for pain. All 23 trials reported data on pain intensity, and 11 trials reported data on functional disability.…”

Section: Resultsmentioning

confidence: 99%

“…This provided a final sample of 23 trials that satisfied the inclusion criteria 30 – 52. Of these, 16 were sponsored by the pharmaceutical industry,31 – 34 36 39 40 43 44 46 – 52 while three others did not state sponsorship but gave an address of a pharmaceutical company as the workplace of most of the authors 37 38 41. The final sample included 10 845 patients, of whom 7767 received NSAIDs and 3078 received placebo (table).…”

Section: Resultsmentioning

confidence: 99%

“…There were more women (67.9%) than men, and the median duration of symptoms was 8.2 years. The weighted mean baseline pain of 64.1 mm on a visual analogue scale was calculated from all but three trials 37 51 52. Six reports provided data of body mass index with a median mean value of 31.2 32 35 38 43 44 48.…”

Section: Resultsmentioning

confidence: 99%

“…One possible limitation of our study is that we included nine trials in which outcomes were recorded with fewer than the five pain dimensions covered by the WOMAC pain subscale 31 32 37 38 41 42 45 47 49. We thought that this, as well as the different time points in the individual studies (2, 3, 4, 6, 12, and 13 weeks) for registering outcome measures, could explain the heterogeneity that was found in the trial results, but heterogeneity persisted after we performed relevant subgroup analyses.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials

Bjordal

Ljunggren

Klovning

et al. 2004

BMJ

391

221

View full text Add to dashboard Cite

Objective To estimate the analgesic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase-2 inhibitors (coxibs), in patients with osteoarthritis of the knee. Design Systematic review and meta-analysis of randomised placebo controlled trials. Studies reviewed 23 trials including 10 845 patients, median age of 62.5 years. 7807 patients received adequate doses of NSAIDs and 3038 received placebo. The mean weighted baseline pain score was 64.2 mm on 100 mm visual analogue scale (VAS), and average duration of symptoms was 8.2 years. Main outcome measure Change in overall intensity of pain. Results Methodological quality of trials was acceptable, but 13 trials excluded patients before randomisation if they did not respond to NSAIDs. One trial provided long term data for pain that showed no significant effect of NSAIDs compared with placebo at one to four years. The pooled difference for pain on visual analogue scale in all included trials was 10.1 mm (95% confidence interval 7.4 to 12.8) or 15.6% better than placebo after 2-13 weeks. The results were heterogeneous, and the effect size for pain reduction was 0.32 (0.24 to 0.39) in a random effects model. In 10 trials that did not exclude non-responders to NSAID treatment the results were homogeneous, with an effect size for pain reduction of 0.23 (0.15 to 0.31). Conclusion NSAIDs can reduce short term pain in osteoarthritis of the knee slightly better than placebo, but the current analysis does not support long term use of NSAIDs for this condition. As serious adverse effects are associated with oral NSAIDs, only limited use can be recommended.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials

Bjordal

Ljunggren

Klovning

et al. 2004

BMJ

391

221

View full text Add to dashboard Cite

show abstract

“…Only one study reported health-related QoL measures with standard deviations, so that they could be metaanalysed. 120 At 6 months there was no significant difference between the meloxicam and the diclofenac groups in the mean change in the QoL measure assessed using the NHP. Both groups improved (WMD -0.10, 95% CI -0.95 to 0.75).…”

Section: Primary Outcomesmentioning

confidence: 99%

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

show abstract

Treatment of intraarticular osteoarthritis of the knee with hylan G-F 20: Comment on the article by Brandt et al

Parenti¹,

Murray²

2001

Arthritis & Rheumatism

View full text Add to dashboard Cite

Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study

Cited by 21 publications

References 10 publications

Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials

Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Treatment of intraarticular osteoarthritis of the knee with hylan G-F 20: Comment on the article by Brandt et al

Contact Info

Product

Resources

About